France ponders off-label Avastin

Share this article:

France is the latest country poised to give the OK to swap Roche's cheaper drug Avastin for the company's pricier eye medication Lucentis. Reuters reports legislators are introducing an amendment to France's social security budget bill that would permit physicians to use Avastin to treat age-related macular degeneration. The amendment's sponsor, Gerard Bapt, says the move could shave around $273 million from annual expenses were doctors to use Avastin, and a vote is due next week.

Italy pulled a similar move last month, and Novartis's reaction is the same as it was then: the company says the off-label use puts patients at risk. Novartis markets the drug in Europe.

“We do not see how reimbursing off-label use for cost reasons in France is justified in the interest of public health,” the company told Reuters Wednesday.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.